Towards Healthcare

NEWS & INSIGHTS

Stay ahead of the curve with in-depth coverage of the latest breakthroughs, emerging trends, strategic developments, and transformative innovations shaping the future of healthcare, science, technology, and global business.

Lilly's progressive journey and contribution, recognised at the global platform
Date 27 November 2025

Lilly's progressive journey and contribution, recognised at the global platform

Announcement Eli Lilly and Company expressed its double excitement by confirming that it will be showcasing the new data from throughout its breast oncology portfolio and the robust pipeline at the ...

NervGen's Peptide reserved for the FDA's regulatory final
Date 27 November 2025

NervGen's Peptide reserved for the FDA's regulatory final

Announcement NervGen’s robust investigational peptide therapeutic, NVG-291, has successfully enhanced the quality of life and improved functional performance in a patient group having chronic ...

FDA reverse tuning delays the biotech's rhythm
Date 26 November 2025

FDA reverse tuning delays the biotech's rhythm

Announcement From July, several biotechs were forced to spin off as existing partnerships with the FDA around proofs needed for approval signalled a reversal. As per the experts, this will put the e...

All eager eyes on Cell and Gene Therapy, sceptical transformational hope
Date 26 November 2025

All eager eyes on Cell and Gene Therapy, sceptical transformational hope

Announcement The sceptical and the headlines creating a debate environment are spotting the cell and gene therapy area of late. The renewal of the efforts and that required motivation is not just wa...

iZafe Group tightens its Nordic Expansion with the smart collaboration
Date 26 November 2025

iZafe Group tightens its Nordic Expansion with the smart collaboration

Announcement iZafe Group has confirmed that it has signed a smart partnership deal with Vakt og Alarm. The Vakt og Alarm is one of Norway’s popular providers of alarm and safety services for t...

AGC Biologics, getting ready to enter the commercial stage, Inherited Retinal Disorders
Date 26 November 2025

AGC Biologics, getting ready to enter the commercial stage, Inherited Retinal Disorders

Announcement After getting near the end of the tunnel with the AAVantgarde closing of the Series B financing round, AGC Biologics is preparing for a new manufacturing agreement with the biotechnolog...

Concept Life Sciences' three new robust data at the centre of the SFN annual meeting
Date 25 November 2025

Concept Life Sciences' three new robust data at the centre of the SFN annual meeting

Announcement Concept Life Sciences, a known contract research organisation (CRO) delivering to the global pharma and Life Sciences industry, has proudly declared that it showcased three new research...

EVQLV's new Abtique, making space and successful headlines for proven AI-Designed Molecules
Date 25 November 2025

EVQLV's new Abtique, making space and successful headlines for proven AI-Designed Molecules

Announcement EVQLV has taken a step ahead in the AI-evolving world to accelerate its business and redefine the healthcare industry's potential values, best aligning with the tech world. The EVQL has...

OS Therapies' plans for converting OS Animal Health into a Standalone Public Company
Date 25 November 2025

OS Therapies' plans for converting OS Animal Health into a Standalone Public Company

Announcement OS Therapies Inc., the champion in listeria-related cancer immunotherapies, is near to offshoot OS Animal Health, Inc. (OSAH) into a standalone public company to be registered on a nati...

FDA's most discussed percentage of drugs and designations highlight
Date 25 November 2025

FDA's most discussed percentage of drugs and designations highlight

Announcement According to the Jefferies analysis, drugs that hold strong designations tend to pass the regulatory process more swiftly, thereby increasing their chances of success. Most of the FDA's...

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.